{"nctId":"NCT00375934","briefTitle":"Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery","startDateStruct":{"date":"2006-09"},"conditions":["Pain, Postoperative"],"count":200,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: diclofenac potassium (XP21L)"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"diclofenac potassium (XP21L)","otherNames":["Zipsor Liquid Filled Capsule","XP21L"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18-65 years of age\n* Have undergone bunionectomy surgery\n* Have achieved adequate post-surgical pain\n\nExclusion Criteria:\n\n* Confounding medical conditions which preclude study participation\n* Participated in a study of another investigational drug or device within 30 days prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy","description":"Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"2.2"},{"groupId":"OG001","value":"5.7","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Perceptible Pain Relief on Day 1","description":"Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"36.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Meaningful Pain Relief on Day 1","description":"Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug","description":"Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"7.4"},{"groupId":"OG001","value":"1.9","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"300","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Required Rescue Medication on Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Required Rescue Medication on Day 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Required Rescue Medication on Day 3","description":"Day 3 data reflect the use of rescue medication only up to the time of discharge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":99},"commonTop":["Nausea","Vomiting","Dizziness","Headache","Somnolence"]}}}